We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioseek | LSE:ATD | London | Ordinary Share | GB0009231639 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMATD
RNS Number : 2031G
Asterand PLC
26 June 2012
26 June 2012
Asterand plc
("Asterand" or the "Company")
Adjournment of Annual General Meeting
The Company announces that its annual general meeting, which was convened for today, has been adjourned and will now take place immediately prior to the general meeting which is to be convened to discuss the proposed disposal of the Human Tissue Business, as announced on 11 June 2012 (the "Disposal"). This adjournment was referred to in the announcement of the Disposal on 11 June 2012.
Jack Davis, the Company's Chairman and Interim Chief Executive Officer, said: "We recognise the importance of what is being proposed and we believe that the posting of the circular to shareholders, which is expected to occur in due course, and the adjourning of the annual general meeting to the same day as the general meeting, to be convened to discuss the Disposal, will enable a full discussion to occur to the benefit of shareholders."
Since the Interim Management Statement announced on 19 May 2012, trading conditions have remained challenging and the ongoing financial constraints have prevented the necessary investment in future growth. As a result, the growth outlook for the Company is diminished in the short term. The Board believes that the Disposal, in assisting to alleviate the current financial constraints, will leave the Company in a stronger financial position overall and better placed for the future.
For further information, please contact:
Asterand plc Jack Davis, Chairman Tel: + 44 (0) 1763 and Interim Chief Executive 211 600 / + 1 (313) Officer 263-0960 Alan Fishman, Interim As above Chief Financial Officer Daniel Stewart & Company Plc Antony Legge Tel: +44 (0) 20 7776 Matt Wilson 6550 Beaumont Cornish Limited - Sponsor Roland Cornish Tel: +44 (0) 20 7628 Emily Staples 3396 Covington Associates LLC Steven Mermelstein Tel: +1 (914) 420-4510 David Wood
A copy of this announcement will be available at www.asterand.co.uk. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGQQLFLLQFFBBB
1 Year Bioseek Chart |
1 Month Bioseek Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions